Clinicopathological risk factors of Stage II colon cancer: Results of a prospective study

Colorectal Disease

Volumn 15, Issue 4, 2013, Pages 414-422

  Santos, C ^a   Lopez Doriga A ^a   Navarro, M ^a   Mateo, J ^a   Biondo, S ^b   Martinez Villacampa M ^a   Soler, G ^a   Sanjuan, X ^b   Paules, M J ^b   Laquente, B ^a   Guino E ^a   Kreisler, E ^b   Frago, R ^b   Germa J R ^a   Moreno, V ^a   Salazar, R ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Adjuvant chemotherapy; Colon cancer; Colorectal surgery; Prognosis

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLORECTAL CANCER; DATA BASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK FACTOR;

AGED; BLOOD VESSELS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERIPHERAL NERVES; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 84875666104     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12028     Document Type: Article

References (36)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
2. O'Connell JB, Maggard MA, Clifford YK. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
4. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of Stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6.
5. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for Stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-407.
6. Schippinger W, Samonigg H, Schaberl-Moser R et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with Stage II colon cancer. Br J Cancer 2007; 97: 1021-7.
7. Van Cutsem E, Dicato M, Wils J et al. Adjuvant treatment of colorectal cancer (current Cancer expert opinion derived from the Third International Conference: Perspectives in Colorectal, Dublin, 2001). Eur J Cancer 2002; 38: 1429-36.
8. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
9. Morris M, Platell C, de Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in Stage II colonic cancer. Br J Surg 2006; 93: 866-71.
10. Kerr D, Gray R, Quirke P et al. A quantitative multigene RT-PCR assay for prediction of recurrence in Stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009; 27: 4000.
11. Roth A, Tejpar DS, Yan R et al. Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009; 27: 4002.
12. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and III colon cancer: who benefits and by how much?J Clin Oncol 2004; 22: 1797-806.
13. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analysed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-9.
14. Jestin P, Påhlman L, Glimelius B, Gunnarsson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer 2005; 41: 2071-8.
15. Quah HM, Chou JF, Gonen M et al. Identification of patients with high-risk Stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51: 503-7.
16. Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery 2000; 127: 370-6.
17. McArdle CS, McMillan DC, Hole DJ. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 2006; 93: 483-8.
18. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997; 185: 55-9.
19. Park YJ, Park KJ, Park J-G, Lee KU, Choe KJ, Kim J-P. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999; 23: 721-6.
20. Hutchins G, Southward K, Handley K. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
21. Roth A, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in Stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
22. Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of Stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
23. Jiang Y, Casey G, Lavery IC et al. Development of a clinically feasible molecular assay to predict recurrence of Stage II colon cancer. J Mol Diagn 2008; 10: 346-54.
24. Maughan NJ, Morris E, Forman D, Quirke P. The validity of the Royal College of Pathologists' colorectal cancer minimum dataset within a population. Br J Cancer 2007; 97: 1393-8.
25. Ho YB, Yun SH, Hong JS et al. Carcinoma obstruction of the left colon and long-term prognosis. Hepatogastroenterology 2008; 55: 1288-92.
26. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010; 134: 837-52.
27. Kingston EF, Goulding H, Bateman AC. Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining. Dis Colon Rectum 2007; 50: 1867-72.
28. Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol 2002; 26: 179-89.
29. Vather R, Sammour T, Zargar-Shoshtari K, Metcalf P, Connolly A, Hill A. Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer. Int J Colorectal Dis 2009; 24: 283-8.
30. Joseph NE, Sigurdson ER, Hanlon AL et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003; 10: 213-8.
31. Kelder W, Inberg B, Schaapveld M et al. Impact of the number of histologically examined lymph nodes on prognosis in colon cancer: a population-based study in the Netherlands. Dis Colon Rectum 2009; 52: 260-7.
32. Jestin P, Nilsson J, Heurgren M, Påhlman L, Glimelius B, Gunnarsson U. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005; 92: 94-100.
33. Abdelrazeq AS, Scott N, Thorn C et al. The impact of spontaneous tumour perforation on outcome following colon cancer surgery. Colorectal Dis 2008; 10: 775-80.
34. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009; 16: 3087-93.
35. Biondo S, Martí-Ragué J, Kreisler E et al. A prospective study of outcomes of emergency and elective surgeries for complicated colonic cancer. Am J Surg 2005; 189: 377-83.
36. O'Connor ES, Greenblatt DY, LoConte NK et al. Adjuvant chemotherapy for Stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29: 3381-8.